The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

The first-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, represent exciting new developments in cancer treatment that offer relevant, rapid, and long-lasting clinical benefits. Larotrectinib and entrectinib are recommended as first-line treatments for locally...

Descripción completa

Detalles Bibliográficos
Autores principales: Liguori, Valerio, Gaio, Mario, Zinzi, Alessia, Cagnotta, Cecilia, Riccardi, Consiglia, Docimo, Giovanni, Capuano, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526334/
https://www.ncbi.nlm.nih.gov/pubmed/37760979
http://dx.doi.org/10.3390/biomedicines11092538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526334/
https://www.ncbi.nlm.nih.gov/pubmed/37760979
http://dx.doi.org/10.3390/biomedicines11092538

Ejemplares similares